The company's flagship product, APCEDEN, was the first Indian FDA-approved immunotherapy product for the treatment of cancer.

APAC's goals are to make APCEDEN personalized immunotherapy available to patients in India and around the world, and to enhance the technology further to explore the uses of personalized immunotherapy in other cancer treatments.